Gusperimus | CAS#98629-43-7 | anti-diabetic

MedKoo Cat#: 584412 | Name: Gusperimus

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gusperimus is synthesized by chemical modification of spergualin and prevents diabetes in predisposed NOD mice in combination with cyclosporin A.

Chemical Structure

Gusperimus

CAS#98629-43-7

Theoretical Analysis

MedKoo Cat#: 584412

Name: Gusperimus

CAS#: 98629-43-7

Chemical Formula: C17H37N7O3

Exact Mass: 387.2958

Molecular Weight: 387.53

Elemental Analysis: C, 52.69; H, 9.62; N, 25.30; O, 12.39

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Gusperimus; Deoxyspergualin; 15-Deoxyspergualin

IUPAC/Chemical Name

Heptanamide, 7-((aminoiminomethyl)amino)-N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-

InChi Key

IDINUJSAMVOPCM-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H37N7O3/c18-9-7-11-21-10-5-6-12-22-15(26)16(27)24-14(25)8-3-1-2-4-13-23-17(19)20/h16,21,27H,1-13,18H2,(H,22,26)(H,24,25)(H4,19,20,23)

SMILES Code

O=C(NC(O)C(NCCCCNCCCN)=O)CCCCCCNC(N)=N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 387.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Perenyei M, Jayne DR, Floßmann O. Gusperimus: immunological mechanism and clinical applications. Rheumatology (Oxford). 2014 Oct;53(10):1732-41. doi: 10.1093/rheumatology/ket451. Epub 2014 Feb 5. Review. PubMed PMID: 24501242. 2: Flossmann O, Jayne DR. Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. Rheumatology (Oxford). 2010 Mar;49(3):556-62. doi: 10.1093/rheumatology/kep411. Epub 2009 Dec 23. PubMed PMID: 20032220. 3: Cheng X, Wang Y, Zhang H, Niu C. [Determination of a major constituent in deoxyspergualin drug by reversed-phase ion-pair chromatography]. Se Pu. 2012 Dec;30(12):1292-4. Chinese. PubMed PMID: 23593889. 4: Banerjee T, Singh RR, Gupta S, Surolia A, Surolia N. 15-Deoxyspergualin hinders physical interaction between basic residues of transit peptide in PfENR and Hsp70-1. IUBMB Life. 2012 Jan;64(1):99-107. doi: 10.1002/iub.583. PubMed PMID: 22223537. 5: Kerr PG, Atkins RC. Deoxyspergualin inhibits cytotoxic T lymphocytes but not NK or LAK cells. Immunol Cell Biol. 1991 Jun;69 ( Pt 3):177-83. PubMed PMID: 1835710. 6: Biffi R, Privitera G, Andreoni B, Matinato C, Pozzi S, Marzona L, Danza M, Rai P, Tiberio G. Luminal bacterial overgrowth and intestinal translocation in pigs given either cyclosporin A or 15-deoxyspergualin after small bowel transplantation. Eur J Surg. 1995 Feb;161(2):93-6. PubMed PMID: 7772637. 7: Di Marco R, Zaccone P, Condorelli L, Leonardi C, Caccamo F, Di Mauro C, Meroni P, Nicoletti F. Deoxyspergualin neither counteracts lipopolysaccharide (LPS) or Staphylococcus aureus enterotoxin-B (SEB) induced lethality in mice nor does it modulate the release of tumor necrosis factor-alpha. Immunol Lett. 1998 Mar;61(1):63-6. PubMed PMID: 9562376. 8: Haberstroh J, Wilhelm T, Schulte-Mönting J, Schorlemmer HU, von Specht BU. Prevention of type I diabetes in the non-obese diabetic (NOD) mouse with 15-deoxyspergualin (15-DS) or 15-DS + cyclosporin A (CyA). Immunol Lett. 1995 Dec;48(2):117-21. PubMed PMID: 8719109. 9: Gannedahl G, Tufveson G, Sundberg B, Groth CG. The effect of plasmapheresis and deoxyspergualin or cyclophosphamide treatment on anti-porcine Gal-alpha (1,3)-Gal antibody titres in humans. Transplant Proc. 1996 Apr;28(2):551. PubMed PMID: 8623262. 10: von Specht BU, Dibelius A, Königsberger H, Lodde G, Roth H, Permanetter W. Prolongation of islet and pancreas graft survival in spontaneous diabetic BB/W rats by perioperative cyclosporin or 15-deoxyspergualin therapy. Transplant Proc. 1989 Feb;21(1 Pt 1):965-7. PubMed PMID: 2495636. 11: Evans CG, Smith MC, Carolan JP, Gestwicki JE. Improved synthesis of 15-deoxyspergualin analogs using the Ugi multi-component reaction. Bioorg Med Chem Lett. 2011 May 1;21(9):2587-90. doi: 10.1016/j.bmcl.2011.02.079. Epub 2011 Mar 1. PubMed PMID: 21420295; PubMed Central PMCID: PMC3088103. 12: Yano K, Fukuda Y, Sumimoto R, Sumimoto K, Ito H, Dohi K. Suppression of liver allograft rejection by administration of 15-deoxyspergualin. Comparison of administration via the hepatic artery, portal vein, or systemic circulation. Transpl Int. 1994 May;7(3):149-56. PubMed PMID: 8060462. 13: Nikolic-Paterson DJ, Tesch GH, Lan HY, Foti R, Atkins RC. Deoxyspergualin inhibits mesangial cell proliferation and major histocompatibility complex class II expression. J Am Soc Nephrol. 1995 May;5(11):1895-902. PubMed PMID: 7620087. 14: Harrison SD Jr, Brockman RW, Trader MW, Laster WR Jr, Griswold DP Jr. Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo. Invest New Drugs. 1987 Dec;5(4):345-51. PubMed PMID: 3436739. 15: Zhu X, Imamura M, Tanaka J, Han CW, Hashino S, Imai K, Asano M, Nakane A, Minagawa T, Kobayashi M, et al. Effects of 15-deoxyspergualin in vitro and in vivo on cytokine gene expression. Transplantation. 1994 Nov 27;58(10):1104-9. PubMed PMID: 7974717. 16: Mae T, Nemoto K, Sugawara Y, Abe F, Takeuchi T. Therapeutic studies of the combination of deoxyspergualin and prednisolone in MRL/lpr mice with advanced lupus-like disease. J Antibiot (Tokyo). 1994 Jan;47(1):90-4. PubMed PMID: 8119866. 17: Thomas JM, Contreras JL, Jiang XL, Eckhoff DE, Wang PX, Hubbard WJ, Lobashevsky AL, Wang W, Asiedu C, Stavrou S, Cook WJ, Robbin ML, Thomas FT, Neville DM Jr. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation. 1999 Dec 15;68(11):1660-73. Retraction in: Marchase RB. Transplantation. 2008 Aug 15;86(3):482. PubMed PMID: 10609942. 18: Muramatsu K, Doi K, Akino T, Shigetomi M, Kawai S. Longer survival of rat limb allograft. Combined immunosuppression of FK-506 and 15-deoxyspergualin. Acta Orthop Scand. 1997 Dec;68(6):581-5. PubMed PMID: 9462361. 19: Kimura Y, Yagi T, Iwagaki H, Watanabe K, Kai K, Yamamura M, Inagaki M, Tanaka S, Tanaka N. Immunomodulation based on a two-way paradigm with deoxyspergualin alleviates graft-versus-host reaction in small-bowel transplantation in rats. J Int Med Res. 2001 May-Jun;29(3):214-21. PubMed PMID: 11471859. 20: Oikawa T, Hasegawa M, Morita I, Murota S, Ashino H, Shimamura M, Kiue A, Hamanaka R, Kuwano M, Ishizuka M, et al. Effect of 15-deoxyspergualin, a microbial angiogenesis inhibitor, on the biological activities of bovine vascular endothelial cells. Anticancer Drugs. 1992 Jun;3(3):293-9. PubMed PMID: 1381973.